At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 703 enrolled
Drug / intervention
0.15% azelastine hydrochloride +1 moredrug
Likely dose
0.15% azelastine hydrochloride 1644 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Active Controlled Trial of the Safety and Tolerability of MP 03-036 (Astepro 0.15%) in Patients With Perennial Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating 0.15% azelastine hydrochloride and Mometasone furoate for Perennial Allergic Rhinitis. Completed, enrolled 703 participants across 59 sites.
Detailed Summary
The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
Primary CompletionJun 2008
Study CompletionJul 2008
First PostedJul 2008
TodayJul 2026
First PostedJul 22, 2008
Enrollment StartMar 1, 2007
Primary CompletionJun 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.9 years ago
Interventions
0.15% azelastine hydrochloridedrug
1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
Mometasone furoatedrug
200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)